2026 EULAR |精粹盘点：SARD-ILD相关PPF管理新进展_

2026 EULAR |精粹盘点：SARD-ILD相关PPF管理新进展

发布时间：2026-06-10

2026年6月3日至6日，欧洲抗风湿病联盟年度大会（EULAR）在伦敦盛大召开。作为全球风湿免疫领域最具影响力的学术盛会之一，本届大会聚集了来自全球的知名专家，呈现了多个领域的前沿学术进展。

间质性肺病（ILD）是自身免疫性疾病（SARD）的严重并发症，SARD-ILD是发展为进展性肺纤维化（PPF）的主要病因^[1-2]。本次EULAR大会多项研究聚焦于SARD相关PPF的研究进展，本期内容对相关研究进行盘点总结。

参考文献：

1.Sebastiani M, et al. Multidisciplinary management of interstitial lung disease in autoimmune rheumatic diseases: an Italian Delphi consensus. Respir Res. 2026 Apr 11.

2.国家卫生健康委办公厅.86 个罕见病病种诊疗指南（2025年版）. https://www.nhc.gov.cn/yzygj/c100068/202507/5b3f41180a42465eb9eec34597bacaf2.shtml

3.Jeffrey A. Sparks, et al. Risk factors for interstitial lung disease in patients with rheumatoid arthritis: results from the international ANCHOR-RA study. 2026 EULAR abstract, OP084.

4.Anna-Maria Hoffmann-Vold, et al. Efficacy of nerandomilast in patients with autoimmune interstitial lung diseases and progressive pulmonary fibrosis in the FIBRONEER-ILD trial. 2026 EULAR abstract, POS0382.

5.Anna-Maria Hoffmann-Vold, et al. Safety and tolerability of nerandomilast in patients with autoimmune disease–related progressive pulmonary fibrosis in the FIBRONEER-ILD trial. 2026 EULAR abstract, POS1207.

6.Toby M. Maher, et al. Predicting long-term survival benefit of nerandomilast in patients with progressive pulmonary fibrosis (PPF) Keywords: Lungs, Prognostic factors. 2026 EULAR abstract, POS1172.

审批号：SC-CN-18691

有效期至2027年6月8日

仅供相关医药专业人士进行医学科学交流